

Immunofluorescence Assay Market by Product (Reagent, Instruments, Antibodies, Kits, Consumables & Accessories), Type (Direct, Indirect), Disease (Infectious Disease, Other Diseases), End User (Contract Research Organizations) – Global Forecast to 2026

<https://marketpublishers.com/r/ID80D3226D3EN.html>

Date: February 2021

Pages: 204

Price: US\$ 4,950.00 (Single User License)

ID: ID80D3226D3EN

Abstracts

The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected to provide growth opportunities for players operating in the immunofluorescence assays market in the coming years. However, quality concerns over antibodies are the major challenge in this market.

“The kits segment accounted for the highest growth rate in the Immunofluorescence assay market, by product, during the forecast period”

The Immunofluorescence assay market is segmented into reagents, instruments, antibodies, kits, and consumables and accessories. The kits segment accounted for the highest growth rate in the Immunofluorescence assay market in 2020. The demand for complete solutions from a single provider, like closed-system reagents with calibrated measurements of the required quantity of reagents and controls, among CROs, academic institutes, and research institutes is growing, contributing to this segment's high growth rate.

“Indirect immunofluorescence segment accounted for the highest CAGR”

Based on type, the immunofluorescence assays market is segmented into indirect immunofluorescence and direct immunofluorescence. In 2020, indirect immunofluorescence accounted for the highest growth rate. The major factors driving the growth of this segment are its advantages such as sensitivity, flexibility, better amplification of the signal, and lower cost over direct immunofluorescence.

“Cancer segment accounted for the highest CAGR”

Based on disease, the immunofluorescence assays market is segmented into cancer, infectious diseases, autoimmune diseases, cardiovascular diseases, and other diseases. In 2020, the cancer segment accounted for the highest growth rate. Increasing prevalence of cancer globally and the widespread adoption of immunofluorescence techniques for the study and diagnosis of cancer are the major factors driving this segment's growth.

“Hospitals & Diagnostic Centers segment accounted for the highest CAGR”

Based on end user, the immunofluorescence assays market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals & diagnostics centers, and contract research organizations. In 2020, the hospitals & diagnostics centers segment accounted for the highest growth rate. This can be attributed to the rising number of cases for various diseases coupled with the increasing number of hospitals worldwide are the major driving factors for this segment's growth.

“Asia Pacific: The fastest-growing country in the Immunofluorescence assay market”

The Immunofluorescence assay market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. Factors such as improving healthcare infrastructure, increasing healthcare spending, and favorable government initiatives are driving the growth of the immunofluorescence assay market in Asia Pacific.

The primary interviews conducted for this report can be categorized as follows:

By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%

By Designation: C-level - 30%, D-level - 34%, and Others - 36%

By Region: North America- 50%, Europe- 32%, APAC-10%, RoW- 8%

Lists of Companies Profiled in the Report:

Thermo Fisher Scientific, Inc. (US)

Abcam plc (UK)

Bio-Rad Laboratories, Inc. (US)

PerkinElmer Inc. (US)

Merck KGaA (Germany)

Werfen Company (Spain)

Cell Signaling Technology, Inc. (US)

MEDIPAN GmbH (Germany)

Sino Biological, Inc. (China)

Danaher Corporation (US)

Maravai LifeSciences (US)

Enzo Biochem, Inc. (US)

Becton, Dickinson and Company (US)

Olympus Corporation (Japan)

Nikon Corporation (Japan)

Bruker Corporation (US)

Agilent Technologies (US)

Zyagen, Inc. (US)

Cellabs (Australia)

J. Mitra & Co. Pvt. Ltd. (India)

Abnova Corporation (Taiwan)

EpiGentek Group (US)

Elabscience, Inc. (US)

AESKU GROUP GmbH (Germany)

MaxVision Biosciences Inc. (Canada)

Research Coverage:

This report provides a detailed picture of the Immunofluorescence assay market. It aims at estimating the size and future growth potential of the market across different segments, such as the product, type, disease, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Immunofluorescence assay market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

Contents

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.2.1 INCLUSIONS & EXCLUSIONS

1.3 MARKET SCOPE

1.3.1 MARKETS COVERED

FIGURE 1 IMMUNOFLUORESCENCE ASSAYS MARKET

1.3.2 YEARS CONSIDERED FOR THE STUDY

1.3.3 CURRENCY

1.4 STAKEHOLDERS

1.5 LIMITATIONS

1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA

FIGURE 2 IMMUNOFLUORESCENCE ASSAYS MARKET: RESEARCH DESIGN

2.1.1 SECONDARY DATA

2.1.1.1 Key data from secondary sources

2.1.2 PRIMARY DATA

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION

2.1.2.1 Key data from primary sources

2.2 MARKET SIZE ESTIMATION

2.2.1 BOTTOM-UP APPROACH

FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH

2.2.2 TOP-DOWN APPROACH

FIGURE 5 TOP-DOWN APPROACH

2.2.3 GROWTH FORECAST

2.3 MARKET BREAKDOWN AND DATA TRIANGULATION

FIGURE 6 DATA TRIANGULATION METHODOLOGY

2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

FIGURE 7 IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2021 VS.

Immunofluorescence Assay Market by Product (Reagent, Instruments, Antibodies, Kits, Consumables & Accessories)...

2026 (USD MILLION)

FIGURE 8 IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2018 VS.

2023 (USD MILLION)

FIGURE 9 IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2021 VS. 2026

(USD MILLION)

FIGURE 10 IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2021 VS.

2026 (USD MILLION)

FIGURE 11 GEOGRAPHIC SNAPSHOT: IMMUNOFLUORESCENCE ASSAYS
MARKET

4 PREMIUM INSIGHTS

4.1 IMMUNOFLUORESCENCE ASSAYS MARKET OVERVIEW

FIGURE 12 RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
GROWTH

4.2 ASIA PACIFIC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE &
COUNTRY (2020)

FIGURE 13 INDIRECT IMMUNOFLUORESCENCE SEGMENT ACCOUNTED FOR
THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2020

4.3 IMMUNOFLUORESCENCE ASSAYS MARKET: GEOGRAPHIC GROWTH
OPPORTUNITIES

FIGURE 14 CHINA TO REGISTER THE HIGHEST GROWTH IN THE FORECAST
PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 KEY MARKET DYNAMICS

FIGURE 15 IMMUNOFLUORESCENCE ASSAYS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES

5.2.1 DRIVERS

5.2.1.1 Increasing prevalence of chronic diseases

TABLE 1 INCIDENCE OF CANCER, 2018 VS. 2040

5.2.1.2 Rising R&D and healthcare spending

FIGURE 16 PHARMACEUTICAL R&D EXPENDITURE, BY GEOGRAPHY, 2010–2016

FIGURE 17 GLOBAL CURRENT HEALTH EXPENDITURE PER CAPITA, 2015–2018

5.2.1.3 Growing industry-academia collaboration

5.2.1.4 Increasing government funding for life science research

TABLE 2 GOVERNMENT FUNDING FOR LIFE SCIENCE RESEARCH (2017-2020)

5.2.1.5 Growing awareness about early disease detection

5.2.2 RESTRAINTS

5.2.2.1 High instrument costs

5.2.3 OPPORTUNITIES

5.2.3.1 High growth opportunities in emerging markets

TABLE 3 DIABETES PREVALENCE IN EMERGING ECONOMIES, 2019 VS. 2030 VS. 2045

5.2.4 CHALLENGES

5.2.4.1 Quality concerns over research antibodies

5.2.4.2 Lack of skilled professionals

TABLE 4 NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018

5.3 COVID-19 IMPACT ON THE IMMUNOFLUORESCENCE ASSAYS MARKET

TABLE 5 IMMUNOFLUORESCENCE ASSAY TESTS APPROVED FOR COVID-19 DIAGNOSTICS

5.4 PRICING ANALYSIS

TABLE 6 IMMUNOFLUORESCENCE ASSAY PRODUCTS, AVERAGE SELLING PRICES (IN USD)

5.5 VALUE CHAIN ANALYSIS

FIGURE 18 MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE

5.6 SUPPLY CHAIN ANALYSIS

FIGURE 19 DIRECT DISTRIBUTION—STRATEGY PREFERRED BY PROMINENT COMPANIES

5.7 ECOSYSTEM ANALYSIS OF THE IMMUNOFLUORESCENCE ASSAYS MARKET

FIGURE 20 ECOSYSTEM ANALYSIS OF THE IMMUNOFLUORESCENCE ASSAYS MARKET

5.8 PESTLE ANALYSIS

6 IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT

6.1 INTRODUCTION

TABLE 7 IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)

6.2 REAGENTS

TABLE 8 IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)

TABLE 9 IMMUNOFLUORESCENCE REAGENTS MARKET, BY COUNTRY,

2019-2026 (USD MILLION)

6.2.1 STAINS & DYES

6.2.1.1 Stains and dyes accounted for the largest share of the reagents segment in 2020

TABLE 10 IMMUNOFLUORESCENCE STAINS & DYES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

6.2.2 MEDIA & SERA

6.2.2.1 Serum-free media eliminates the risk of contamination by viruses

TABLE 11 IMMUNOFLUORESCENCE MEDIA & SERA MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

6.2.3 FIXATIVES

6.2.3.1 Fixative agents are required for the preservation of morphology and the antigenicity of target molecules

TABLE 12 IMMUNOFLUORESCENCE FIXATIVES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

6.2.4 BUFFERS

6.2.4.1 Buffers are widely used in drug development applications

TABLE 13 IMMUNOFLUORESCENCE BUFFERS MARKET, BY COUNTRY, 2019-2026(USD MILLION)

6.2.5 PROBES

6.2.5.1 The use of probes in research is rising owing to its versatile and quantitative capabilities

TABLE 14 IMMUNOFLUORESCENCE PROBES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

6.2.6 SOLVENTS

6.2.6.1 Organic solvents are widely used in pharmaceutical processes and immunofluorescence assays

TABLE 15 IMMUNOFLUORESCENCE SOLVENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

6.2.7 OTHER REAGENTS

TABLE 16 OTHER IMMUNOFLUORESCENCE REAGENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

6.3 INSTRUMENTS

TABLE 17 IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)

TABLE 18 IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

6.3.1 MICROSCOPES

6.3.1.1 Technological advancements in microscopy techniques propel segment

growth

TABLE 19 IMMUNOFLUORESCENCE MICROSCOPES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

6.3.2 IMAGING ANALYSIS SYSTEMS

6.3.2.1 Imaging analysis systems are widely used in diagnostics and clinical research

TABLE 20 IMMUNOFLUORESCENCE IMAGING ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

6.4 ANTIBODIES

TABLE 21 IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026(USD MILLION)

TABLE 22 IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

6.4.1 PRIMARY ANTIBODIES

6.4.1.1 The increasing demand for accurate and reliable antibodies coupled with rising R&D expenditure drives segment growth

TABLE 23 PRIMARY IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

6.4.2 SECONDARY ANTIBODIES

6.4.2.1 The low cost of production and versatility have ensured stable growth in the market for secondary antibodies

TABLE 24 SECONDARY IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

6.5 KITS

6.5.1 THE DEMAND FOR COMPLETE SOLUTIONS AMONG END USERS DRIVES THE GROWTH OF THIS SEGMENT

TABLE 25 IMMUNOFLUORESCENCE KITS MARKET, BY COUNTRY, 2019-2026(USD MILLION)

6.6 CONSUMABLES & ACCESSORIES

TABLE 26 IMMUNOFLUORESCENCE CONSUMABLES & ACCESSORIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

7 IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE

7.1 INTRODUCTION

TABLE 27 GLOBAL IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 28 COMPARISON BETWEEN DIRECT AND INDIRECT IMMUNOFLUORESCENCE TECHNIQUES

7.2 INDIRECT IMMUNOFLUORESCENCE

7.2.1 INDIRECT IMMUNOFLUORESCENCE ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2020

TABLE 29 GLOBAL INDIRECT IMMUNOFLUORESCENCE ASSAYS MARKET, BY REGION/COUNTRY, 2019–2026 (USD MILLION)

7.3 DIRECT IMMUNOFLUORESCENCE

7.3.1 THE HIGH COST ASSOCIATED WITH DIRECT IMMUNOFLUORESCENCE MAY LIMIT THE GROWTH OF THIS MARKET

TABLE 30 GLOBAL DIRECT IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

8 IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE

8.1 INTRODUCTION

TABLE 31 IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)

8.2 CANCER

8.2.1 CANCER ACCOUNTED FOR THE LARGEST SHARE OF THE DISEASE SEGMENT IN 2020

TABLE 32 CANCER PREVALENCE, BY TYPE (2018)

TABLE 33 GLOBAL CANCER INCIDENCE, 2018 VS. 2025

TABLE 34 IMMUNOFLUORESCENCE ASSAYS MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD MILLION)

8.3 INFECTIOUS DISEASES

8.3.1 THE RISING PREVALENCE OF INFECTIOUS DISEASES TO INCREASE THE ADOPTION OF IMMUNOFLUORESCENCE ASSAY TECHNIQUES

TABLE 35 IMMUNOFLUORESCENCE ASSAYS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)

8.4 CARDIOVASCULAR DISEASES

8.4.1 THE HIGH INCIDENCE OF CVD TO INCREASE THE ADOPTION OF IMMUNOFLUORESCENCE IMAGING TECHNIQUES

TABLE 36 IMMUNOFLUORESCENCE ASSAYS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)

8.5 AUTOIMMUNE DISEASES

8.5.1 THE PREVALENCE OF AUTOIMMUNE DISEASES HAVE INCREASED WORLDWIDE, THUS SUPPORTING THE GROWTH OF THIS SEGMENT

TABLE 37 PREVALENCE OF AIDS

TABLE 38 IMMUNOFLUORESCENCE ASSAYS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)

8.6 OTHER DISEASES

TABLE 39 IMMUNOFLUORESCENCE ASSAYS MARKET FOR OTHER DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)

9 IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER

9.1 INTRODUCTION

TABLE 40 IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026(USD MILLION)

9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

9.2.1 PHARMA & BIOTECH COMPANIES ACCOUNTED FOR THE LARGEST SHARE OF THE END-USER SEGMENT IN 2020

TABLE 41 IMMUNOFLUORESCENCE ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2019-2026 (USD MILLION)

9.3 ACADEMIC & RESEARCH INSTITUTES

9.3.1 GROWING GOVERNMENT INVESTMENTS FOR R&D TO PROPEL MARKET GROWTH

TABLE 42 IMMUNOFLUORESCENCE ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY/REGION, 2019-2026 (USD MILLION)

9.4 HOSPITALS & DIAGNOSTIC CENTERS

9.4.1 THE RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT THE GROWTH OF THIS SEGMENT

TABLE 43 IMMUNOFLUORESCENCE ASSAYS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY/REGION, 2019-2026 (USD MILLION)

9.5 CONTRACT RESEARCH ORGANIZATIONS

9.5.1 EMERGING MARKETS ARE EXPECTED TO PROVIDE ROBUST GROWTH OPPORTUNITIES FOR CROS

TABLE 44 IMMUNOFLUORESCENCE ASSAYS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY/REGION, 2019-2026(USD MILLION)

10 IMMUNOFLUORESCENCE ASSAY MARKET, BY REGION

10.1 INTRODUCTION

TABLE 45 IMMUNOFLUORESCENCE ASSAYS MARKET, BY REGION, 2019–2026 (USD MILLION)

10.2 NORTH AMERICA

FIGURE 21 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, SNAPSHOT

TABLE 46 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY

COUNTRY, 2019–2026 (USD MILLION)

TABLE 47 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 48 NORTH AMERICA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 49 NORTH AMERICA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 50 NORTH AMERICA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 51 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 52 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)

TABLE 53 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)

10.2.1 US

10.2.1.1 The US dominates the North American market in terms of market share
TABLE 54 US NIH BUDGET FOR VARIOUS DISCIPLINES, FY 2019 VS. FY 2020 (USD BILLION)

TABLE 55 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 56 US: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 57 US: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 58 US: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 59 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 60 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)

TABLE 61 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)

10.2.2 CANADA

10.2.2.1 Support from government organizations is driving the growth of the immunofluorescence assays market in Canada

TABLE 62 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 63 CANADA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,

2019–2026 (USD MILLION)

TABLE 64 CANADA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 65 CANADA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 66 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 67 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)

TABLE 68 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)

10.3 EUROPE

TABLE 69 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

TABLE 70 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 71 EUROPE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 72 EUROPE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 73 EUROPE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 74 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 75 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)

TABLE 76 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)

10.3.1 GERMANY

10.3.1.1 Germany holds the largest share of the European market

TABLE 77 RESEARCH GRANTS PROVIDED IN GERMANY, 2015–2019

TABLE 78 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 79 GERMANY: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 80 GERMANY: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 81 GERMANY: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 82 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 83 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)

TABLE 84 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)

10.3.2 UK

10.3.2.1 Growing R&D investments drive the market in the UK

TABLE 85 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 86 UK: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 87 UK: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 88 UK: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 89 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 90 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)

TABLE 91 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)

10.3.3 FRANCE

10.3.3.1 Rising research activity supports market growth in France

TABLE 92 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 93 FRANCE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 94 FRANCE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 95 FRANCE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 96 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 97 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)

TABLE 98 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)

10.3.4 ITALY

10.3.4.1 Rising life science R&D and favorable funding scenario are key drivers of the Italian market

TABLE 99 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 100 ITALY: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 101 ITALY: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 102 ITALY: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 103 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 104 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)

TABLE 105 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)

10.3.5 SPAIN

10.3.5.1 Rising prevalence of chronic disease to support the market growth

TABLE 106 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 107 SPAIN: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 108 SPAIN: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 109 SPAIN: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 110 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 111 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)

TABLE 112 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)

10.3.6 REST OF EUROPE

TABLE 113 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 114 ROE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 115 ROE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 116 ROE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019–2026 (USD MILLION)

TABLE 117 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019–2026 (USD MILLION)

TABLE 118 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019–2026 (USD MILLION)

TABLE 119 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019–2026 (USD MILLION)

10.4 ASIA PACIFIC

FIGURE 22 ASIA PACIFIC: IMMUNOFLUORESCENCE ASSAYS MARKET
SNAPSHOT

TABLE 120 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY,
2019-2026 (USD MILLION)

TABLE 121 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2019-2026 (USD MILLION)

TABLE 122 APAC: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,
2019-2026 (USD MILLION)

TABLE 123 APAC: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE,
2019-2026 (USD MILLION)

TABLE 124 APAC: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019-2026 (USD MILLION)

TABLE 125 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019-2026 (USD MILLION)

TABLE 126 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019-2026 (USD MILLION)

TABLE 127 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019-2026 (USD MILLION)

10.4.1 JAPAN

10.4.1.1 Japan is the largest market for immunofluorescence assays
in the APAC

TABLE 128 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2019-2026 (USD MILLION)

TABLE 129 JAPAN: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,
2019-2026 (USD MILLION)

TABLE 130 JAPAN: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE,
2019-2026 (USD MILLION)

TABLE 131 JAPAN: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019-2026 (USD MILLION)

TABLE 132 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,

2019-2026 (USD MILLION)

TABLE 133 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019-2026 (USD MILLION)

TABLE 134 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019-2026 (USD MILLION)

10.4.2 CHINA

10.4.2.1 China is the fastest-growing market for immunofluorescence assays

TABLE 135 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2019-2026 (USD MILLION)

TABLE 136 CHINA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,
2019-2026 (USD MILLION)

TABLE 137 CHINA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE,
2019-2026 (USD MILLION)

TABLE 138 CHINA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019-2026 (USD MILLION)

TABLE 139 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019-2026 (USD MILLION)

TABLE 140 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019-2026 (USD MILLION)

TABLE 141 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019-2026 (USD MILLION)

10.4.3 INDIA

10.4.3.1 Increasing government spending on healthcare to support market growth

TABLE 142 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,
2019-2026 (USD MILLION)

TABLE 143 INDIA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE,
2019-2026 (USD MILLION)

TABLE 144 INDIA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE,
2019-2026 (USD MILLION)

TABLE 145 INDIA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE,
2019-2026 (USD MILLION)

TABLE 146 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE,
2019-2026 (USD MILLION)

TABLE 147 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE,
2019-2026 (USD MILLION)

TABLE 148 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER,
2019-2026 (USD MILLION)

10.4.4 REST OF ASIA PACIFIC

TABLE 149 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT,

2019-2026 (USD MILLION)

TABLE 150 ROAPAC: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)

TABLE 151 ROAPAC: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)

TABLE 152 ROAPAC: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)

TABLE 153 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)

TABLE 154 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)

TABLE 155 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)

10.5 LATIN AMERICA

10.5.1 GROWING CONTRACT RESEARCH & MANUFACTURING ACTIVITIES TO SUPPORT MARKET GROWTH

TABLE 156 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)

TABLE 157 LATIN AMERICA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)

TABLE 158 LATIN AMERICA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)

TABLE 159 LATIN AMERICA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)

TABLE 160 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)

TABLE 161 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)

TABLE 162 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)

10.6 MIDDLE EAST & AFRICA

10.6.1 INADEQUATE RESEARCH INFRASTRUCTURE TO HAMPER THE MARKET GROWTH IN THE REGION

TABLE 163 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)

TABLE 164 MEA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)

TABLE 165 MEA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)

TABLE 166 MEA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)

TABLE 167 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)

TABLE 168 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)

TABLE 169 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW

FIGURE 23 KEY DEVELOPMENTS IN THE IMMUNOFLUORESCENCE ASSAYS MARKET (2017 TO 2020)

11.2 MARKET SHARE ANALYSIS

FIGURE 24 IMMUNOFLUORESCENCE REAGENTS, KITS, ANTIBODIES, AND CONSUMABLE & ACCESSORIES MARKET SHARE, BY KEY PLAYER (2019)

FIGURE 25 IMMUNOFLUORESCENCE INSTRUMENTS MARKET SHARE, BY KEY PLAYER (2019)

11.3 COMPETITIVE SCENARIO

11.3.1 MARKET EVALUATION FRAMEWORK, 2017-2020

11.3.2 PRODUCT LAUNCHES & APPROVALS

TABLE 170 PRODUCT LAUNCHES & APPROVALS

11.3.3 AGREEMENTS & COLLABORATIONS

TABLE 171 AGREEMENTS & COLLABORATIONS

11.3.4 ACQUISITIONS

TABLE 172 ACQUISITIONS

11.3.5 EXPANSIONS

TABLE 173 EXPANSIONS

11.3.6 OTHER DEVELOPMENTS

TABLE 174 OTHER DEVELOPMENTS

11.4 COMPANY EVALUATION MATRIX DEFINITION AND METHODOLOGY

11.4.1 VENDOR EXCLUSION CRITERIA

11.4.2 STARS

11.4.3 EMERGING LEADERS

11.4.4 PERVASIVE PLAYERS

11.4.5 PARTICIPANTS

FIGURE 26 IMMUNOFLUORESCENCE ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING

11.5 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES

11.5.1 PROGRESSIVE COMPANIES

11.5.2 STARTING BLOCKS

11.5.3 RESPONSIVE COMPANIES

11.5.4 DYNAMIC COMPANIES

FIGURE 27 IMMUNOFLUORESCENCE ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES

12 COMPANY PROFILES

(Business overview, Products offered, Recent developments & MnM View)*

12.1 THERMO FISHER SCIENTIFIC, INC.

FIGURE 28 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019)

12.2 ABCAM PLC

FIGURE 29 ABCAM PLC: COMPANY SNAPSHOT (2020)

12.3 BIO-RAD LABORATORIES, INC.

FIGURE 30 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2019)

12.4 PERKINELMER, INC.

FIGURE 31 PERKINELMER: COMPANY SNAPSHOT (2019)

12.5 MERCK KGAA

FIGURE 32 MERCK KGAA: COMPANY SNAPSHOT (2019)

12.6 WERFEN COMPANY

FIGURE 33 WERFEN COMPANY: COMPANY SNAPSHOT (2019)

12.7 CELL SIGNALING TECHNOLOGY, INC.

12.8 MEDIPAN GMBH

12.9 SINO BIOLOGICAL, INC.

12.10 DANAHER CORPORATION

FIGURE 34 DANAHER CORPORATION: COMPANY SNAPSHOT (2019)

12.11 MARAVAI LIFESCIENCES

FIGURE 35 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2019)

12.12 ENZO BIOCHEM, INC.

FIGURE 36 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2019)

12.13 BECTON, DICKINSON AND COMPANY (BD)

FIGURE 37 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)

12.14 OLYMPUS CORPORATION

FIGURE 38 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2020)

12.15 NIKON CORPORATION

FIGURE 39 NIKON CORPORATION: COMPANY SNAPSHOT (2020)

12.16 BRUKER CORPORATION

12.17 AGILENT TECHNOLOGIES

12.18 ZYAGEN, INC.

12.19 CELLABS

12.20 J. MITRA & CO. PVT. LTD.

12.21 ABNOVA CORPORATION

12.22 EPIGENTEK GROUP

12.23 ELABSCIENCE, INC.

12.24 AESKU.GROUP GMBH

12.25 MAXVISION BIOSCIENCES, INC.

*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.

13 APPENDIX

13.1 INDUSTRY INSIGHTS

13.2 DISCUSSION GUIDE

13.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL

13.4 AVAILABLE CUSTOMIZATIONS

13.5 RELATED REPORTS

13.6 AUTHOR DETAILS

I would like to order

Product name: Immunofluorescence Assay Market by Product (Reagent, Instruments, Antibodies, Kits, Consumables & Accessories), Type (Direct, Indirect), Disease (Infectious Disease, Other Diseases), End User (Contract Research Organizations) – Global Forecast to 2026

Product link: <https://marketpublishers.com/r/ID80D3226D3EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ID80D3226D3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970